These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 24452758)

  • 1. Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics.
    Mukherji D; Omlin A; Pezaro C; Shamseddine A; de Bono J
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):555-66. PubMed ID: 24452758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
    Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
    Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment options in castration-resistant prostate cancer: current therapies and emerging docetaxel-based regimens.
    Saad F; Miller K
    Urol Oncol; 2014 Feb; 32(2):70-9. PubMed ID: 23506965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapies for metastatic castration-resistant prostate cancer.
    El-Bahesh E; Finianos A; Alfaraj A; Aragon-Ching JB
    Future Oncol; 2015; 11(17):2395-403. PubMed ID: 26274603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SEOM clinical guidelines for the treatment of metastatic prostate cancer.
    Cassinello J; Climent MA; González del Alba A; Mellado B; Virizuela JA;
    Clin Transl Oncol; 2014 Dec; 16(12):1060-6. PubMed ID: 25319721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.
    Bahl A; Masson S; Birtle A; Chowdhury S; de Bono J
    Cancer Treat Rev; 2014 Feb; 40(1):170-7. PubMed ID: 23958310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic castration resistant prostate cancer: current strategies of management in the Middle East.
    Bazarbashi S; Bachour M; Bulbul M; Alotaibi M; Jaloudi M; Jaafar H; Mukherji D; Farah N; Alrubai T; Shamseddine A
    Crit Rev Oncol Hematol; 2014 Apr; 90(1):36-48. PubMed ID: 24289901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.
    Fitzpatrick JM; Bellmunt J; Fizazi K; Heidenreich A; Sternberg CN; Tombal B; Alcaraz A; Bahl A; Bracarda S; Di Lorenzo G; Efstathiou E; Finn SP; Fosså S; Gillessen S; Kellokumpu-Lehtinen PL; Lecouvet FE; Oudard S; de Reijke TM; Robson CN; De Santis M; Seruga B; de Wit R
    Eur J Cancer; 2014 Jun; 50(9):1617-27. PubMed ID: 24703899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy.
    Omlin A; Pezaro C; Gillessen Sommer S
    Ther Adv Urol; 2014 Feb; 6(1):3-14. PubMed ID: 24489604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequencing of agents for castration-resistant prostate cancer.
    Hurwitz M; Petrylak DP
    Oncology (Williston Park); 2013 Nov; 27(11):1144-9, 1154-8. PubMed ID: 24575543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabazitaxel in metastatic castration-resistant prostate cancer.
    Yap TA; Pezaro CJ; de Bono JS
    Expert Rev Anticancer Ther; 2012 Sep; 12(9):1129-36. PubMed ID: 23098113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current, new and novel therapy for castration-resistant prostate cancer.
    Gaya JM; Ahallal Y; Sanchez-Salas R; Barret E; Rozet F; Galiano M; Macek P; Durand M; Cerruti J; Prapotnich D; Ropert S; Bennamoun M; Cathelineau X
    Expert Rev Anticancer Ther; 2013 Jul; 13(7):819-27. PubMed ID: 23875660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and emerging agents for the treatment of castration-resistant prostate cancer.
    Higano CS; Crawford ED
    Urol Oncol; 2011; 29(6 Suppl):S1-8. PubMed ID: 22074657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How to approach sequencing therapy in patients with metastatic castration resistant prostate cancer.
    Dreicer R
    Can J Urol; 2014 Apr; 21(2 Supp 1):93-7. PubMed ID: 24775730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radium-223 for the treatment of prostate cancer.
    Hafeez S; Parker C
    Expert Opin Investig Drugs; 2013 Mar; 22(3):379-87. PubMed ID: 23316941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy.
    Drake CG; Sharma P; Gerritsen W
    Oncogene; 2014 Oct; 33(43):5053-64. PubMed ID: 24276248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current therapeutic options in metastatic castration-resistant prostate cancer.
    Ingrosso G; Detti B; Scartoni D; Lancia A; Giacomelli I; Baki M; Carta G; Livi L; Santoni R
    Semin Oncol; 2018 Oct; 45(5-6):303-315. PubMed ID: 30446166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.